newsfilter
← Latest News
GlobeNewswire·

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

COSM
  • Cosmos Health reported record Q2 and H1 2026 revenue of $18.99 million and $36.91 million respectively, reflecting a 28.8% and 29.7% year-over-year increase.
  • The company achieved a new milestone with an adjusted annualized revenue run-rate exceeding $75 million.
  • Adjusted gross margin expanded 165 basis points to 9.54% in Q2, while adjusted EBITDA improved 13.8% year-over-year.
  • Operating expenses grew at roughly half the rate of revenue, demonstrating operating leverage, while inventory decreased 21.8% despite nearly 30% revenue growth.
  • Total liabilities decreased 13.3% by $6.27 million to $40.79 million, with stockholders' equity rising 12.2% to $20.67 million.
  • Liquid assets totaled $4.15 million, comprising cash, marketable securities, and digital assets.
  • The company repurchased 2,650,000 shares for approximately $513,000 in Q2, with total repurchases reaching 5,112,000 shares for approximately $1.11 million.
  • CosmoFarm added over 75 new pharmacies to its distribution network, achieving a $60+ million annualized run-rate.
  • Decahedron nearly doubled its revenue in the United Kingdom, while Cana Laboratories built its contract manufacturing orderbook to an all-time high of over 25 million units.
  • The company entered the U.S. skincare market and launched the "18 Series" nutraceutical platform targeting liver health, joint support, and men's wellness.
  • C-Scrub Wash 4% completed testing under EN 12791, opening hospital channels, and the company entered the animal health industry with a veterinary formulation.
  • The Board authorized a $5.0 million share repurchase program expiring December 31, 2026.
  • 4,874,126 Series B warrants expired unexercised, eliminating approximately 38% of total warrant overhang.
  • The company signed a letter of intent to acquire Doc Pharma S.A. and identified approximately $20 million in non-core assets for monetization.